Pliant Therapeutics Inc (PLRX)
26.61
+0.07
(+0.26%)
USD |
NASDAQ |
Mar 31, 16:00
26.57
-0.04
(-0.15%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.568B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 279.6% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 115.36 |
| Price to Book Value | 5.005 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0317 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
MT Newswires
03/20 10:00
MT Newswires
03/13 12:21
MT Newswires
03/13 10:21
MT Newswires
03/10 08:57
MT Newswires
03/10 08:29
MT Newswires
03/10 08:02
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/09/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 03/09/2023 | -- | Results | Q4 2022 | -0.72 | -0.70 | -2.86% | |
| 11/08/2022 | -- | Results | Q3 2022 | -0.65 | -0.74 | 12.53% | |
| 08/08/2022 | -- | Results | Q2 2022 | -0.82 | -0.81 | -0.70% | |
| 05/09/2022 | -- | Results | Q1 2022 | -0.78 | -0.74 | -5.12% | |
| 02/28/2022 | -- | Results | Q4 2021 | -0.68 | -0.75 | 9.09% | |
| 11/09/2021 | -- | Results | Q3 2021 | -0.75 | -0.69 | -9.09% | |
| 08/09/2021 | -- | Results | Q2 2021 | -0.64 | -0.67 | 4.41% |
*Estimated Date/Time
Earnings
Profile
| Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis. |
| URL | https://www.pliantrx.com |
| Investor Relations URL | https://ir.pliantrx.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 09, 2023 (est.) |
| Last Earnings Release | Mar. 09, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 31, 2023.
Fundamentals
| Revenue (TTM) | 9.685M |
| Total Expenses (TTM) | 136.88M |
| Net Income (TTM) | -123.32M |
| Total Assets (Quarterly) | 350.61M |
| Total Liabilities (Quarterly) | 37.27M |
| Shareholders Equity (Quarterly) | 313.34M |
| Cash from Operations (TTM) | -94.63M |
| Cash from Investing (TTM) | -150.20M |
| Cash from Financing (TTM) | 226.85M |
Ratings
Profile
| Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis. |
| URL | https://www.pliantrx.com |
| Investor Relations URL | https://ir.pliantrx.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 09, 2023 (est.) |
| Last Earnings Release | Mar. 09, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| F00001F5M7 | 292998.0 USD | 2.93% |
| LCMGX | 5.469M USD | 2.37% |
| LHCSX | 99128.00 USD | 1.45% |
| BBC | 158420.0 USD | 1.30% |
| FRBRX | 9.574M USD | 1.17% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| PLRX Tweets |